Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 53

Results For "EY"

3746 News Found

Lonza expands cell and gene therapy portfolio
Biotech | October 07, 2025

Lonza expands cell and gene therapy portfolio

Lonza boosts TheraPEAK line with new Cytokines and AAV Medium for next-gen therapies


Health Secretary Srivastava chairs meeting with states/UTs on quality and rational use of cough syrups
Policy | October 06, 2025

Health Secretary Srivastava chairs meeting with states/UTs on quality and rational use of cough syrups

States exhorted to ensure rational use of cough syrups, particularly among children, as most coughs are self-limiting and do not require pharmacological treatment


AGC Pharma Chemicals opens new €100 million manufacturing plant in Spain
News | October 06, 2025

AGC Pharma Chemicals opens new €100 million manufacturing plant in Spain

It represents a 30% increase in the company’s production capacity and introduces a segment dedicated to highly potent active ingredients


India invites applications under PRIP scheme to drive pharma-medtech innovation
R&D | October 06, 2025

India invites applications under PRIP scheme to drive pharma-medtech innovation

Early stage projects of up to Rs. 9 crore eligible for up to Rs. 5 crore assistance and later stage projects of up to Rs. 285 crore eligible for up to Rs. 100 crore assistance


Lilly to invest $1 billion+ in new contract manufacturing in India
News | October 06, 2025

Lilly to invest $1 billion+ in new contract manufacturing in India

Investment to expand manufacturing and global medicine supply capacity


AbbVie’s Natrelle awarded supplier agreement from Vizient
News | October 05, 2025

AbbVie’s Natrelle awarded supplier agreement from Vizient

This agreement grants Vizient clients enhanced access to Natrelle, the broadest selection of breast implant options on the market


BMS’s anti-MTBR-Tau granted fast track designation by FDA for Alzheimer’s disease
Drug Approval | October 05, 2025

BMS’s anti-MTBR-Tau granted fast track designation by FDA for Alzheimer’s disease

Anti-microtubule binding region-tau antibody being investigated as a potential disease-modifying therapy to slow or delay progression of disease


Amgen’s Phase III data supports FDA label expansion of Repatha
News | October 05, 2025

Amgen’s Phase III data supports FDA label expansion of Repatha

Repatha is now the first and only PCSK9 inhibitor to demonstrate significant reduction of cardiovascular events as both primary and secondary prevention